CN101821257B - 5-ht7受体拮抗剂 - Google Patents

5-ht7受体拮抗剂 Download PDF

Info

Publication number
CN101821257B
CN101821257B CN2008801107600A CN200880110760A CN101821257B CN 101821257 B CN101821257 B CN 101821257B CN 2008801107600 A CN2008801107600 A CN 2008801107600A CN 200880110760 A CN200880110760 A CN 200880110760A CN 101821257 B CN101821257 B CN 101821257B
Authority
CN
China
Prior art keywords
compound
methyl
pyrazoles
ethyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801107600A
Other languages
English (en)
Chinese (zh)
Other versions
CN101821257A (zh
Inventor
V·O·巴德斯库
S·A·费拉
P·T·加拉赫尔
M·A·华顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101821257A publication Critical patent/CN101821257A/zh
Application granted granted Critical
Publication of CN101821257B publication Critical patent/CN101821257B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801107600A 2007-10-12 2008-09-30 5-ht7受体拮抗剂 Expired - Fee Related CN101821257B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97946407P 2007-10-12 2007-10-12
US60/979464 2007-10-12
PCT/US2008/078294 WO2009048765A1 (en) 2007-10-12 2008-09-30 5-ht7 receptor antagonists

Publications (2)

Publication Number Publication Date
CN101821257A CN101821257A (zh) 2010-09-01
CN101821257B true CN101821257B (zh) 2013-05-22

Family

ID=40134870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801107600A Expired - Fee Related CN101821257B (zh) 2007-10-12 2008-09-30 5-ht7受体拮抗剂

Country Status (19)

Country Link
US (1) US7910588B2 (enExample)
EP (1) EP2201002B1 (enExample)
JP (1) JP5291716B2 (enExample)
KR (1) KR101161070B1 (enExample)
CN (1) CN101821257B (enExample)
AT (1) ATE548365T1 (enExample)
AU (1) AU2008311154B2 (enExample)
BR (1) BRPI0818450A2 (enExample)
CA (1) CA2699674C (enExample)
CY (1) CY1112709T1 (enExample)
DK (1) DK2201002T3 (enExample)
EA (1) EA016787B1 (enExample)
ES (1) ES2380756T3 (enExample)
HR (1) HRP20120257T1 (enExample)
MX (1) MX2010003986A (enExample)
PL (1) PL2201002T3 (enExample)
PT (1) PT2201002E (enExample)
SI (1) SI2201002T1 (enExample)
WO (1) WO2009048765A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI396857B (zh) * 2009-12-30 2013-05-21 Etron Technology Inc 晶片測試電路
BR112014008588A2 (pt) 2011-10-11 2017-04-18 Ucb Pharma Sa derivados de 2-oxo-piperidinila
ES2804545T3 (es) 2013-03-11 2021-02-08 Univ Temple Nuevos moduladores de la actividad del receptor de 5-hidroxitriptamina 7 y su método de uso
TW201601632A (zh) * 2013-11-20 2016-01-16 杜邦股份有限公司 １－芳基－３－烷基吡唑殺蟲劑
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
IL291029B2 (en) 2016-11-15 2024-06-01 Univ Temple New modulators of 5-hydroxytryptamine receptor 7 and a method of using them
EP3600289A4 (en) 2017-03-21 2020-08-05 Temple University - Of The Commonwealth System of Higher Education 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067703A2 (en) * 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
US20030008880A1 (en) 2001-05-02 2003-01-09 Pfizer Inc. 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
US7211783B2 (en) 2004-01-09 2007-05-01 Tamperproof Container Licensing Corp. Tamper-proof container
KR20070034524A (ko) 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
TW200914020A (en) * 2007-08-28 2009-04-01 Lilly Co Eli Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067703A2 (en) * 2003-01-31 2004-08-12 Pfizer Products Inc. 5ht7 antagonists and inverse agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. Leopoldo.Serotonin7 Receptors (5-HT7Rs) and their Ligands.《Current Medicinal Chemistry》.2004,第11卷(第5期),629-661. *

Also Published As

Publication number Publication date
ES2380756T3 (es) 2012-05-18
CN101821257A (zh) 2010-09-01
HRP20120257T1 (hr) 2012-04-30
KR20100054853A (ko) 2010-05-25
US20100197700A1 (en) 2010-08-05
SI2201002T1 (sl) 2012-04-30
CA2699674C (en) 2013-07-16
ATE548365T1 (de) 2012-03-15
BRPI0818450A2 (pt) 2015-05-12
KR101161070B1 (ko) 2012-07-13
WO2009048765A1 (en) 2009-04-16
EA201070462A1 (ru) 2010-10-29
JP2011500575A (ja) 2011-01-06
EA016787B1 (ru) 2012-07-30
JP5291716B2 (ja) 2013-09-18
PT2201002E (pt) 2012-04-27
EP2201002A1 (en) 2010-06-30
CA2699674A1 (en) 2009-04-16
PL2201002T3 (pl) 2012-07-31
US7910588B2 (en) 2011-03-22
AU2008311154A1 (en) 2009-04-16
CY1112709T1 (el) 2016-02-10
AU2008311154B2 (en) 2013-09-26
MX2010003986A (es) 2010-04-27
DK2201002T3 (da) 2012-04-10
EP2201002B1 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
CN101821257B (zh) 5-ht7受体拮抗剂
US9056867B2 (en) N-substituted heterocyclyl carboxamides
EP0675118B1 (en) Biphenylderivatives, process for their preparation and their use as medicaments
ES2297205T3 (es) Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica.
CA2621255A1 (en) Amido compounds and their use as pharmaceuticals
CN104844566B (zh) 一种新型结构的激酶抑制剂
PT1499589E (pt) Derivados de n- fenil ( piperidin-2-il ) metilbenzamida, sua preparação e sua aplicação em terapêutica
JP4906715B2 (ja) ４，５−ジ置換−２−アリールピリミジン類
AU2012335978A1 (en) Modulators of the G protein-coupled Mas receptor and the treatment of disorders related thereto
PT2364185E (pt) Ftalazina dissubstituída antagonista da via hedgehog
ES2446307T3 (es) Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
US20240374738A1 (en) Bifunctional compound capable of degrading receptor tyrosine kinase and application thereof
EA017809B1 (ru) Замещённые пиперазинилпиразины и пиридины в качестве антагонистов рецепторов 5-нт
JP2008513451A (ja) ４−アリールスピロシクロアルキル−２−アミノピリミジンカルボキサミドｋｃｎｑカリウムチャネル調節剤
DE69525633T2 (de) Chinoxalinderivate und ihre therapeutische verwendbarkeit
CN102884048B (zh) 用作hcn阻滞剂的氨基杂芳基衍生物
EP2234992A2 (en) Piperazine derivatives and their use as leptin receptor modulators
WO2005063720A1 (ja) アミド誘導体及び医薬
US20020143023A1 (en) Dihydropyrimidine compounds and compositions containing the same
CA2707822A1 (en) New compounds iii
SK286687B6 (sk) Sulfónamidy, spôsob ich výroby, medziprodukty, liečivo a farmaceutická kompozícia s ich obsahom
KR20110021958A (ko) 소분자 렙틴 수용체 조절제
TW201141485A (en) Compounds and their use
CN101711234A (zh) 作为皮层儿茶酚胺能神经传递调节剂的新型二取代的苯基吡咯烷
JP2009526844A (ja) ピペラジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130522

Termination date: 20180930